GSK1904529A

Product Name: GSK1904529A
CAS No.: 1089283-49-7
Chemical Name: GSK1904529A
Synonyms: CS-29;GSK 4529;GSK1904529A;GSK1904529A, >=98%;GSK1904529A ，S1093;GSK1904529A (GSK-4529;IGF-IR, IGF-IIR inhibitor;GSK1904529A, 10 mM in DMSO;IGF-1R inhibitor GS1904529A;GSK1904529A ISO 9001：2015 REACH
CBNumber: CB92501005
Molecular Formula: C44H47F2N9O5S
Formula Weight: 851.96
MOL File: 1089283-49-7.mol

More

Less

GSK1904529A Property

Density: 1.39
storage temp.: Store at -20°C
solubility: ≥42.6 mg/mL in DMSO; insoluble in EtOH; insoluble in H2O
form: solid
pka: 11.12±0.70(Predicted)
color: Light yellow to yellow
InChIKey: MOSKATHMXWSZTQ-UHFFFAOYSA-N
SMILES: C(NC1=C(F)C=CC=C1F)(=O)C1=CC(C2=C(C3C=CN=C(NC4=CC(CC)=C(N5CCC(N6CCN(S(C)(=O)=O)CC6)CC5)C=C4OC)N=3)N3C(=N2)C=CC=C3)=CC=C1OC

More

Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word: Warning

More

Less

N-Bromosuccinimide Price

Sigma-Aldrich

Product number: SML3675
Product name: GSK1904529A
Purity: ≥98% (HPLC)
Packaging: 5mg
Price: $145.35
Updated: 2025/07/31

Sigma-Aldrich

Product number: SML3675
Product name: GSK1904529A
Purity: ≥98% (HPLC)
Packaging: 25mg
Price: $616
Updated: 2025/07/31

Cayman Chemical

Product number: 29155
Product name: GSK1904529A
Packaging: 5mg
Price: $116
Updated: 2024/03/01

Cayman Chemical

Product number: 29155
Product name: GSK1904529A
Packaging: 25mg
Price: $456
Updated: 2024/03/01

Cayman Chemical

Product number: 29155
Product name: GSK1904529A
Packaging: 1mg
Price: $32
Updated: 2024/03/01

More

Less

GSK1904529A Chemical Properties,Usage,Production

Uses

A selective inhibitor of IGF-1R and IR with IC50s of 27 nM and 25 nM, respectively.

Uses

GSK 1904529A is a small-molecule inhibitor of the insulin-like growth factor-I receptor tyrosine kinase.

Definition

ChEBI: N-(2,6-difluorophenyl)-5-[3-[2-[5-ethyl-2-methoxy-4-[4-(4-methylsulfonyl-1-piperazinyl)-1-piperidinyl]anilino]-4-pyrimidinyl]-2-imidazo[1,2-a]pyridinyl]-2-methoxybenzamide is a member of benzamides.

Biological Activity

gsk1904529a is a small-molecule inhibitor of the insulin-like growth factor-i receptor (igf-ir) with ic50 value of 27 nm 1.gsk1904529a is a reversible and atp-competitive inhibitor with ki value of 1.6 nm. in nih-3t3/lisn cells, gsk1904529a potently inhibited phosphorylation of igf-ir with ic50 value of 22 nm. it also demonstrated to be a selective inhibitor since it showed poor inhibitory activity against 45 other serine/threonine and tyrosine kinases. when treated with whole-cell extracts, gsk1904529a significantly inhibited the ligand-induced phosphorylation of igf-ir and decreased phosphorylation of downstream signaling including akt, irs-1 and erk at concentrations > 0.01μm. gsk1904529a suppressed cell proliferation in a variety of tumor cells. the ic50 values for nci-h929, tc-71, sk-n-mc, colo 205, mcf7 and prec are 81, 35, 43, 124, 137 and 68 nm, respectively. in colo 205, mcf-7, and nci-h929 cells, gsk1904529a treatment resulted in cell accumulation in g1 and decrease in s and g2-m phases. moreover, in nih-3t3/lisn xenograft model, once daily administration of gsk1904529a at 30 mg/kg inhibited 56% of tumor growth 1.

in vivo

GSK1904529A (30 mg/kg; p.o. once or twice daily for 21 d) has antitumor activity in mice^[1].
GSK1904529A (1-30 mg/kg; a single p.o.) decreases IGF-I-induced IGF-IR phosphorylation in a dose-dependent manner in mice^[1].
GSK1904529A (30 mg/kg; p.o. once or twice daily for 21 d) has no significant alterations in the blood glucose levels in mice^[1].

Animal Model:	Female athymic nu/nu CD-1 mice are bring NIH-3T3/LISN tumor^[1]
Dosage:	30 mg/kg
Administration:	P.o. once or twice daily for 21 d
Result:	Resulted in 56% (once daily) and 98% (twice daily) inhibition of tumor growth. No significant decrease in body weight on the once-daily schedule. Observed 11-13% of body weight loss, and recovered to near baseline 6 days after the cessation of treatment in twice-daily group.

target

IGF1R

References

1. sabbatini p, rowand j l, groy a, et al. antitumor activity of gsk1904529a, a small-molecule inhibitor of the insulin-like growth factor-i receptor tyrosine kinase. clinical cancer research, 2009, 15(9): 3058-3067.

GSK1904529A Preparation Products And Raw materials

Raw materials

Preparation Products

More

Less

GSK1904529A Suppliers

China 114 India 2 United States 22 Global 138

Chuzhou KeMail Chemical Technology Co., Ltd

Tel: 0550-5196001 15000891977
Fax: 0550-5196001
Email: wj520wjxby@126.com
Country: China
ProdList: 1944
Advantage: 55

Shanghai Boyle Chemical Co., Ltd.

Tel
Fax: 86-21-57758967
Email: sales@boylechem.com
Country: China
ProdList: 2922
Advantage: 55

Chembest Research Laboratories Limited

Tel: +86-21-20908456
Fax: 021-58180499
Email: sales@BioChemBest.com
Country: China
ProdList: 6003
Advantage: 61

JinYan Chemicals(ShangHai) Co.,Ltd.

Tel: 13817811078
Fax: 86-021-50426522,50426273
Email: sales@jingyan-chemical.com
Country: China
ProdList: 9976
Advantage: 60

Nanjing Chemlin Chemical Co., Ltd

Tel: 025-83697070
Fax: +86-25-83453306
Email: info@chemlin.com.cn
Country: China
ProdList: 15883
Advantage: 64

Jinan Trio PharmaTech Co., Ltd.

Tel: 0531-88811783
Fax: +86 (531) 55696010 QQ 1762738062
Email: sales@trio-pharmatech.com
Country: China
ProdList: 1856
Advantage: 62

Dalian Meilun Biotech Co., Ltd.

Tel: 0411-62910999 13889544652
Email: sales@meilune.com
Country: China
ProdList: 4747
Advantage: 58

Shanghai PharmaChem CO.,Ltd.

Tel: 13621878384
Fax: 13621878384
Email: wm_pharchem@163.com
Country: China
ProdList: 20
Advantage: 60

NCE Biomedical Co.,Ltd.

Tel: 4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988
Fax: +86-27-87599188
Country: China
ProdList: 1493
Advantage: 55

Nanjing Norris-Pharm Technology Co., Ltd

Tel: 18652989687
Fax: +86-25-52131256
Email: sales@norris-pharm.com
Country: China
ProdList: 8878
Advantage: 55

More

Less

View Lastest Price from GSK1904529A manufacturers

Shaanxi Dideu Medichem Co. Ltd

Product: GSK1904529A 1089283-49-7
Price: US $1.10/g
Min. Order: 1g
Purity: 99.0% min
Supply Ability: 100 tons min
Release date: 2021-05-12

1089283-49-7, GSK1904529ARelated Search:

4-Aminodiphenylamine AZD-4547 Bortezomib MK-2206 2HCl PD 0332991 HCl Crizotinib Olaparib

CS-29

GSK1904529A;GSK-1904529A;GSK 1904529A

GSK 4529

GSK1904529A

GSK1904529A : IGF-IR, IGF-IIR inhibitor

N-(2,6-Difluorophenyl)-5-[3-[2-[[5-ethyl-2-(methyloxy)-4-[4-[4-(methylsulfonyl)-1-piperazinyl]-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]imidazo[1,2-a]pyridin-2-yl]-2-(methyloxy)benzamide

N-(2,6-difluorophenyl)-5-(3-(2-(5-ethyl-2-methoxy-4-(4-(4-(methylsulfonyl)piperazin-1-yl)piperidin-1-yl)phenylamino)pyrimidin-4-yl)H-imidazo[1,2-a]pyridin-2-yl)-2-methoxybenzamide

N-(2,6-Difluorophenyl)-5-[3-[2-[[5-ethyl-2-(methyloxy)-4-[4-[4-(methylsulfonyl)-1-piperazinyl]-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]imidazo[1,2-a]pyridin-2-yl]-2-(methyloxy)benzamide GSK 1904529A

GSK1904529A, >=98%

IGF-IR, IGF-IIR inhibitor

N-(2,6-Difluorophenyl)-5-[3-[2-[[5-ethyl-2-(methyloxy)-4-[4-[4-(methylsulfonyl)-1-piperazinyl]

Benzamide, N-(2,6-difluorophenyl)-5-[3-[2-[[5-ethyl-2-methoxy-4-[4-[4-(methylsulfonyl)-1-piperazinyl]-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]imidazo[1,2-a]pyridin-2-yl]-2-methoxy-

GSK1904529A ISO 9001：2015 REACH

GSK1904529A (GSK-4529

N-(2,6-Difluorophenyl)-5-(3-(2-((5-ethyl-2-methoxy-4-(4-(4-(methylsulfonyl)piperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)imidazo[1,2-a]pyridin-2-yl)-2-methoxybenzamide

IGF-1R inhibitor GS1904529A

GSK1904529A, 10 mM in DMSO

GSK1904529A ，S1093

1089283-49-7

C44H47F2N9O5S

Inhibitors